Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Norway
  4. Oslo Bors
  5. Targovax ASA
  6. News
  7. Summary
    TRVX   NO0010689326


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Targovax : receives Fast Track designation for ONCOS-102 in melanoma

06/22/2021 | 12:22am EDT
  • The US FDA grants ONCOS-102 Fast Track designation for PD-1-refractory advanced melanoma
  • Fast Track designation further strengthens the opportunity for accelerated approval for ONCOS-102 in melanoma

Oslo, Norway 22 June 2021 - Targovax ASA (OSE: TRVX), a clinical stage immune-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that its lead clinical candidate ONCOS-102 has received Fast Track designation in PD-1-refractory advanced melanoma from the US FDA.  

The US FDA has granted Fast Track designation to ONCOS-102 based on the current pre-clinical and clinical data package, including mechanistic evidence showing an association between ONCOS-102-induced immune activation and tumor responses. Receiving this designation is an endorsement by the US FDA of the strength and importance of the ONCOS-102 data package in PD-1-refractory advanced melanoma. This Fast Track approval comes in addition to ONCOS-102´s existing Fast Track designation in malignant pleural mesothelioma.

The FDA Fast Track designation is awarded to therapies with potential to address unmet medical needs in serious medical conditions and allows for more frequent interactions with the FDA to expedite clinical development, as well as the regulatory review processes. Fast Track products have high likelihood of receiving Priority Review for a future Biologics License Application (BLA) and may be allowed to submit parts of the application for rolling review to shorten the approval timeline.

Dr. Ingunn Munch Lindvig, VP Regulatory Affairs of Targovax said: "Securing yet another Fast Track designation is a strong endorsement of the potential for ONCOS-102 to benefit a patient population with high unmet medical need. Fast Track simplifies and expedites the regulatory interactions and review process, and further supports the rationale for initiating a Phase 2 trial to target accelerated approval for ONCOS-102 in anti-PD1 refractory melanoma".

For further information, please contact:
Oystein Soug, CEO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

IR enquires:
Kim Sutton Golodetz - LHA Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777

About Targovax

Activating the patient's immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax aims to unlock greater clinical benefits in cancer patients by deploying multifunctional platforms to target key immune regulators and oncogenic drivers. Targovax's focus is to "activate the patient's immune system to fight cancer", thus extending and transforming the lives of cancer patients. Targovax's pipeline aims at different cancer indications, including melanoma, mesothelioma and colorectal cancer. The products are designed to harness the patient's own immune system to fight the cancer, whilst also delivering a favorable safety and tolerability profile.

Targovax's lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. On the back of very encouraging data in several indications, in monotherapy and in multiple combination, the next development steps for ONCOS-102 will involve a clinical trial with registration intent in checkpoint inhibitor refractory melanoma.


This information is considered to be inside information pursuant to the EU Market Abuse Regulation, and is subject to disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act. The stock exchange announcement was published by Renate Birkeli, Investor Relations, Targovax ASA.


(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about TARGOVAX ASA
07/12TARGOVAX : announces resignation of Chief Financial Officer, Torbjorn Furuseth
07/09TARGOVAX : CFO to Step Down
07/09TARGOVAX : announces resignation of Chief Financial Officer, Torbjørn Furuseth
07/09TARGOVAX : announces resignation of Chief Financial Officer, Torbjørn Furuseth
07/09Targovax Asa Announces Resignation of Torbjørn Furuseth as Chief Financial Of..
07/02TARGOVAX ASA : issues options to new member of management
07/01TARGOVAX ASA : appoints Dr Lone Ottesen as Chief Development Officer
07/01Targovax ASA Appoints Lone Ottesen as Chief Development Officer
06/28TARGOVAX : to present at the 4th Annual Next Gen Immuno-Oncology Virtual Congres..
06/22Targovax Gets FDA Fast-Track Designation for ONCOS-102 in Melanoma
More news
Sales 2021 0,27 M 0,03 M 0,03 M
Net income 2021 -117 M -13,2 M -13,2 M
Net cash 2021 137 M 15,5 M 15,5 M
P/E ratio 2021 -5,60x
Yield 2021 -
Capitalization 649 M 73,2 M 73,2 M
EV / Sales 2021 1 918x
EV / Sales 2022 2 651x
Nbr of Employees 20
Free-Float 86,6%
Duration : Period :
Targovax ASA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TARGOVAX ASA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 3
Last Close Price 7,49 NOK
Average target price 15,67 NOK
Spread / Average Target 109%
EPS Revisions
Managers and Directors
Øystein Soug Chief Executive Officer
Torbjørn Furuseth Chief Financial Officer
Damian Marron Chairman
Magnus Jaderberg Chief Medical Officer
Victor Levitsky Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
WUXI APPTEC CO., LTD.37.17%71 226
BIONTECH SE245.88%55 555